A D3 Bio (Wuxi) Co. Ltd. patent describes heterocyclic-substituted pyrimidopyran compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

KRAS G12C is the most common form of KRAS mutation in lung cancer, while G12D is found more commonly in other diseases like pancreatic and colorectal cancers. Dr Hu Tao, co-founder and chief ...

Jazz’s move into the KRAS category comes shortly after AstraZeneca licensed a KRAS G12D inhibitor from Chinese biotech Usynova for $24 million upfront in a deal that also includes up to $395 ...

The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide expert advice on some of the most pressing challenges facing the nation and world. Our ...

Nature Machine Intelligence publishes high-quality original research and reviews in a wide range of topics in machine learning, robotics and AI. We also explore and discuss the significant impact ...

Oct. 7, 2024 — New research shows that international conservation efforts account for approximately 10 percent of fish stocks on coral ...

In cancer, and particularly in the presence of oncogenic KRAS mutations, in vivo studies concluded that SG increase the resistance of cancer cells to stress. Hence, SG have recently been considered a ...

Multidisciplinary research, such as a study of heart disease during and after cancer therapy, is a key strategy for advancement of cancer survivorship care. Beyond Cancer: Confronting the ...

The Global Nature Positive Summit will accelerate collective action to drive investment in nature and strengthen activities to protect and repair our environment. It will bring together leaders from ...

The emerging role of cardiovascular magnetic resonance in refining the diagnosis of hypertrophic cardiomyopathy.